Biomimedica, Inc., is located in Berkeley, California, and was founded in 2007. A Stanford University spin-off, the company is led by a group of orthopaedic medical device and clinical experts. Biomimedica is a private, VC-backed company, dedicated to pioneering innovative treatments for cartilage damage and osteoarthitis. The core material technology was developed for more than three years at Stanford University by a team of world-renowned material science and bioengineering experts.
Our mission is to bring people with joint diseases back to an active lifestyle while limiting the associated health care costs.
Our management team, board of directors and clinical advisory board are comprised of industry-recognized professionals that lead the technology, clinical, regulatory and marketing efforts with a focus on successful commercialization in Europe and the US.
Allan has been a founder, board member and/or CEO of a number of early stage companies in medical device and biotechnology, including Athenagen, MAST Immunosystems, Intella Interventional Systems, Quanam Medical, ImmuneTech, NuGEN Technologies, AngstroVision, IntegriGen, Imetrx, and Vascular Architects. Previously, Mr. May was Senior Vice President of Diasonics, Inc., a NYSE-listed medical imaging company manufacturing and distributing MRI, ultrasound, fluoroscopic and therapeutic devices, and President and COO of Fortune Systems Corporation, a NASDAQ-traded developer of microprocessor based file servers utilizing the Unix operating system. He also has extensive experience in negotiating and consummating mergers and acquisitions, having been involved in over 100 transactions. He co-founded Life Science Angels (“LSA”) in 2005 and currently serves as its Chairman. LSA is the largest angel organization in the United States comprised solely of life science industry veterans and investing solely in medical device and life science early stage companies.
John has more than twenty-five years of leadership experience in the medical device industry spanning three continents. He most recently worked for Zimmer, Inc., a publicly traded company, where he held a succession of increasingly complex positions including, President Spine/Trauma, President Asia-Pacific, President Japan, Chairman Zimmer KK, and Vice President/General Manager Canada, Latin America and Asia Pacific operations. John was head of Business Development when Zimmer Holdings acquired Swiss-based Centerpulse AG in 2003. He was also a part of the senior management team that made Zimmer a publicly traded company in August, 2001. John is currently president and CEO of Fziomed, which has developed superior biomaterials for orthopaedic/spine, gynecology/general and aesthetic surgery.
Gary Fanton, MD
Dr. Fanton is the Chief of the Section of Sports Medicine in the Department of Orthopedic Surgery at Stanford School of Medicine. His practice primarily involves the diagnostic evaluation and treatment of sports and trauma-related injuries of the upper extremity, knee, and ankle. He is Board Certified by the American Board of Orthopedic Surgery and is currently the Team Physician in Orthopedics for the San Francisco 49ers. Dr. Fanton's past experience includes positions as team orthopedist for the San Francisco Giants, company physician for the San Jose Ballet, head team orthopedist for Stanford University football and basketball, and team orthopedist for Stanford’s additional 29 varsity sports. He co-founded the SOAR clinic where he was an active partner in private practice since 1983. He holds a B.S. from the University of Michigan and an M.D. from the Medical College of Wisconsin.
Graham Crooke, MD
Dr. Crooke brings over 17 years of venture capital experience and six years of medical and operating experience. Prior to co-founding Helix Ventures in 2008 he led the life sciences investment effort at Asset Management Company. Graham also co-founded and was a partner at Ticonderoga Capital, a private equity firm that was spun out of Dillon, Read & Co. Inc., a New York investment bank, in 1997. At Ticonderoga, he was responsible for evaluating and monitoring a broad portfolio of health care investments from three partnerships. Before helping to form Ticonderoga, he was a partner of Dillon Read Venture Capital and vice president of Dillon, Read & Co. Inc., where he was responsible for evaluating and managing life sciences investments. Graham graduated in 1983 with an MB.BS. in medicine (M.D. equivalent) from the University of Western Australia and spent three years as a practicing physician at teaching hospitals in Perth, Australia. He received his M.B.A. from the Stanford Graduate School of Business in 1988. He sits on the board of Insmed, Inc., a public biotech company (“INSM”), and several private companies.